Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis

In the OPERA I and II randomized clinical trials, continuous OCR treatment over 10 years provided greater benefit in preserving function than a 2-year delay in initiating OCR, reinforcing the importance of early high-efficacy treatment.

Corresponding Author: Stephen L. Hauser, MD, UCSF Weill Institute for Neurosciences, University of California, San Francisco, 1651 4th St, San Francisco, CA, 94158 (stephen.hauser@ucsf.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.